Browse 90 Cervical Cancer Medical Studies Across 369 Cities
11 Phase 3 Trial · 1118 Cervical Cancer Clinics
What Are Cervical-Cancer Clinical Trials
Cervical cancer is when cells of the cervix adversely change. The cancer is typically a result of an infection with HPV (human papillomavirus). It is generally diagnosed after a Pap smear (Papanicolaou test).
Cervical cancer rarely produces symptoms at the early stages.
Cervical cancer is primarily either adenocarcinoma or squamous cell carcinoma (the most common).
In the 1970s, the HPV virus was detected by Dr. Harald zur Hausen, who went on to show that an HPV infection is related to cervical cancer. Clinical trials for cervical cancer primarily focus on treatments and early detection techniques.
Why Is Cervical-Cancer Being Studied Through Clinical Trials?
According to the CDC, cervical-cancer impacts 13,000 new people in the United States each year. The World Health Organization ranks it the fourth most common cancer in women, estimating that 570,000 women were diagnosed in 2018.
According to WHO, cervical cancers are some of the most treatable types of cancer, provided it is detected early. Thus, many clinical trials focus on improving early detection techniques. At present, Pap tests are the primary screening method. However, HPV DNA testing is also used. Some clinical trials are looking into new and improved HPV testing.
However, once cervical cancer has become persistent, treatments have traditionally only had a success rate of around 50%. Clinical trials are looking at ways to raise the percentage of positive outcomes.
Prevention of HPV infection is a crucial component of reducing cervical cancer. 2006 was the first time the FDA approved an HPV vaccine for teen girls and young women.
By 2021, 50% of the world was using an HPV vaccine, and many European countries had expanded their vaccination program to include boys. Consequently, the CDC has seen an 88% reduction in genital warts in teen girls and 81% in adult women, alluding to fewer HPV infections.
What Are The Types Of Treatments Available For Cervical-Cancer?
Cervical cancer is primarily treated by surgery when caught in the early stages. However, those diagnosed later often require chemotherapy and or radiation.
However, targeted treatments are emerging. 2021, tisotumab, an antibody drug, was approved by the FDA. 2021 was also when the KEYNOTE-826 trial published promising results for adding immunotherapy to treatment for patients with more advanced stages of cervical cancer.
Clinical trials for immunotherapy examine their safety, the percentage of improvement over chemotherapy alone, and if combining types of immunotherapies raises positive outcomes.
What Are Some Recent Breakthrough Clinical Trials For Cervical-Cancer?
2021: Immunotherapy, Pembrolizumab: Merck & Co funded the Phase 3 KEYNOTE-826 trial. It looked into using Keytruda (pembrolizumab) with chemotherapy as a treatment for patients with metastatic or recurrent cervical cancer. The double-blind trial involved 617 patients. The study showed positive outcomes went from 48%-50% to 66%.
2021: Immunotherapy, Balstilimab – Agenus Inc funded a study where researchers from various Gynecologic divisions, including James Comprehensive Cancer Center, Massey Cancer Center, and Oklahoma Cancer center, examined using balstilimab alone or with zalifrelimab, which work at different immune checkpoints. It is an approach that has been effectively used with other cancers.